Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Smoking 1Multiple Myeloma 1Leukemia, Plasma Cell 1Hematologic Neoplasms 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1

Interventions

Carboplatin 195Cisplatin 117Paclitaxel 107Pemetrexed 106Docetaxel 96Gemcitabine 89Radiotherapy 83Erlotinib Hydrochloride 58Bevacizumab 55Etoposide 49durvalumab 39pembrolizumab 38Nivolumab 31Specimen Handling 30Magnetic Resonance Spectroscopy 30Irinotecan 27Radiosurgery 26osimertinib 24Gefitinib 24Drug Therapy 23Vinorelbine 22atezolizumab 20Topotecan 20Radiation 16Cetuximab 16Taxes 15Surgical Procedures, Operative 14Neoadjuvant Therapy 13Filgrastim 13Chemotherapy, Adjuvant 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lung Neoplasms × Budesonide × Clear all
NCT00321893 2016-01-25

Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
225 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Smoking, Small Cell Lung Carcinoma

NCT00005880 2008-07-24

Budesonide in Treating Former and Current Smokers With Bronchial Dysplasia

National Cancer Institute (NCI)

Phase 2 Completed
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡